Skip to main navigation Skip to search Skip to main content

Rare manifestations and malignancies in tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increAse disease awareness (TOSCA)

  • the TOSCA investigators
  • Klinikum Kempten
  • Pirogov Russian National Research Medical University
  • SPS Pediatrična Klinika
  • TSA Tuberous Sclerosis Association
  • Universite Claude Bernard Lyon 1
  • University of Rome Tor Vergata
  • Karolinska Institutet
  • Novartis Farma SpA
  • Association Sclérose Tubéreuse de Bourneville
  • University of Cape Town
  • Centro Hospitalar Lisboa Ocidental
  • Medical University of Vienna
  • Associazione Sclerosi Tuberosa ONLUS
  • In Den Birken
  • Vivantes Netzwerk für Gesundheit GmbH
  • Medical University of Warsaw
  • Children's Memorial Health Institute
  • Sydney Children's Hospital
  • University Hospital Vall d'Hebron
  • University of Leon
  • Laboratory of embryology and genetics of human malformations
  • University College London
  • Peking University
  • Children Mental Health Centre of Tallinn Children Hospital
  • Novartis
  • National Hospital Organization Shizuoka Institute of Epilepsy and Neurological Disorders
  • Hôpital Nord, CHU de Saint-Étienne
  • Aghia Sophia Children's Hospital
  • Utrecht University
  • Vrije Universiteit Brussel
  • St. George's University of London

Research output: Contribution to journalArticlepeer-review

32 Scopus citations

Abstract

Background: Tuberous sclerosis complex (TSC) is a rare multisystem autosomal dominant disorder caused by pathogenic variants in either the TSC1 or TSC2 gene. Common manifestations of TSC have been grouped into major and minor clinical diagnostic criteria and assessed in clinical routine workup. However, case studies point towards the existence of rare disease manifestations and to the potential association of TSC with malignant tumors. In this study we sought to characterize rare manifestations and malignancies using a large cohort of patients. Methods: TuberOus SClerosis registry to increAse disease awareness (TOSCA) is a multicenter, international disease registry collecting clinical manifestations and characteristics of patients with TSC, both retrospectively and prospectively. We report rates and characteristics of rare manifestations and malignancies in patients with TSC who had enrolled in the TOSCA registry. We also examined these manifestations by age, sex, and genotype (TSC1 or TSC2). Results: Overall, 2211 patients with TSC were enrolled in the study. Rare manifestations were reported in 382 (17.3%) study participants and malignancies in 65 (2.9%). Of these rare manifestations, the most frequent were bone sclerotic foci (39.5%), scoliosis (23%), thyroid adenoma (5.5%), adrenal angiomyolipoma (4.5%), hemihypertrophy and pancreatic neuroendocrine tumors (pNET; both 3.1%). These rare manifestations were more commonly observed in adults than children (66.2% vs. 22.7%), in females versus males (58.4% vs. 41.6%; except for scoliosis: 48.9% vs. 51.1%), and in those with TSC2 versus TSC1 (67.0% vs. 21.1%; except for thyroid adenoma: 42.9% vs. 57.1%). In the 65 individuals with reported malignancies, the most common were renal cell carcinoma (47.7%), followed by breast (10.8%) and thyroid cancer (9.2%). Although malignancies were more common in adult patients, 26.1% were reported in children and 63.1% in individuals < 40 years. TSC1 mutations were over-represented in individuals with malignancies compared to the overall TOSCA cohort (32.1% vs. 18.5%). Conclusion: Rare manifestations were observed in a significant proportion of individuals with TSC. We recommend further examination of rare manifestations in TSC. Collectively, malignancies were infrequent findings in our cohort. However, compared to the general population, malignant tumors occurred earlier in age and some tumor types were more common.

Original languageEnglish
Article number301
JournalOrphanet Journal of Rare Diseases
Volume16
Issue number1
DOIs
StatePublished - Dec 2021

Funding

FundersFunder number
Boehringer Ingelheim
Actelion Pharmaceuticals
Gilead Sciences
European Commission
Novartis
Roche
Seventh Framework Programme602391
GlaxoSmithKline
Pfizer
Novartis Pharma
Japan Society for the Promotion of Science21K07788
Narodowe Centrum Badań i RozwojuSTRATEGMED3/306306/4/2016

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    Keywords

    • Malignancy
    • Rare manifestation
    • TOSCA
    • TSC
    • Tuberous sclerosis complex

    Fingerprint

    Dive into the research topics of 'Rare manifestations and malignancies in tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increAse disease awareness (TOSCA)'. Together they form a unique fingerprint.

    Cite this